Merck ($MRK) prevails in appeals court on Temodar patent
Merck's ($MRK) Schering-Plough unit won an appeals court ruling that revives its effort to block Teva Pharmaceutical Industries ($TEVA) from selling a generic form of the brain-cancer drug Temodar until 2013. Report
Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product
Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.